Biopharmaceutical company Biocon's third quarter profit is likely to increase 38 percent year-on-year to Rs 142 crore and revenue may grow 15.5 percent to Rs 965.7 crore.
According to average of estimates of analysts polled by CNBC-TV18, operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) is seen rising 32.5 percent to Rs 240 crore and margin may expand 220 basis points to 24 percent compared with year-ago period.
Revenue growth is expected to pick up during the quarter while licensing income is likely to be subdued at around Rs 7 crore in Q3.
Analysts expect Syngene to lead growth with the contract research growth of 15-20 percent YoY. In Q2, Syngene growth was slower than expected at 14 percent against expectations of over 20 percent YoY.
They expect 12-14 percent in Bio-pharma sales. Within Bio-pharma, branded formulation sales may be impacted by discontinued oncology drug Abraxane sales.
Bio-pharma sales have regrouped under 3 segments - small molecules, branded formulations and biologics.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
